Anticancer therapy targeting the erbB family of receptor tyrosine kinases

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The erbB family of receptor tyrosine kinases plays a crucial role in cell growth and proliferation.
• Dysregulation of erbB signaling is implicated in various cancers, making them attractive therapeutic targets.
• Existing treatments often face limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

• To review the current clinical investigation of agents targeting the erbB family of receptor tyrosine kinases.
• To summarize the efficacy and toxicities of key therapeutic agents.
• To explore the potential roles of these agents in cancer treatment, including combination and maintenance therapies.

Main Methods:

• Review of clinical trial data and preclinical studies for erbB-targeting agents.
• Analysis of efficacy and safety profiles of monoclonal antibodies (trastuzumab, C225) and tyrosine kinase inhibitors (ZD1839, OSI-774, CI-1033).
• Evaluation of therapeutic strategies, including monotherapy and combination therapy with cytotoxic drugs.

Main Results:

• Trastuzumab demonstrates efficacy in erbB2-expressing metastatic breast cancer, with notable toxicities.
• C225 shows encouraging antitumor activity against the epidermal growth factor receptor.
• Orally active tyrosine kinase inhibitors exhibit promising antitumor activity in preclinical and early clinical settings.

Conclusions:

• Agents targeting erbB receptors hold significant potential in cancer therapy.
• Combined therapeutic approaches are likely to enhance response rates to cytotoxic drugs.
• Long-term monotherapy may be valuable for maintaining response and preventing disease recurrence.